Advertisement

Determination of the DNA Sequence Specificity of Alkylation Damage Using Cleavage-Based Assays

  • John A. Hartley
  • Michael D. Wyatt
Part of the Methods in Molecular Biology™ book series (MIMB, volume 90)

Abstract

Many agents that possess antitumor activity have been shown to bind to DNA. Several clinically used chemotherapeutic drugs are alkylating agents, which are known to bind covalently to, and in many cases crosslink, the bases of DNA. These include the nitrogen mustard, chloroethyl-nitrosourea, triazene, and dimethanesulfonate classes of agents. Most simple alkylating agents of this type show a base specificity for guanine, binding primarily to the guanine-N7 position in the major groove of DNA (1). In contrast, more complex agents such as the natural product CC-1065 and the novel agent tallimustine bind primarily to adenine bases at the N3 position in the minor groove (2,3). In addition to this base specificity it is now apparent that many, if not all antitumor agents that bind to DNA, do so with some degree of base-sequence selectivity. This can vary from agents such as nitrogen mustards, which show a limited discrimination between the target base in different sequence contexts, to those such as CC-1065 and talhinustine, which show a high degree of selectivity to certain unique sequences, with the corresponding avoidance of others.

Keywords

Minor Groove Nitrogen Mustard Ethidium Bromide Solution Bacterial Alkaline Phosphatase Thermal Cleavage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hemminki K. and Ludlum D. B. (1984) Covalent modification of DNA by antineoplastic agents. J Natl Cancer Inst 73, 1021–1028Google Scholar
  2. 2.
    Broggini M., Coley H., Mongelli N., Grandi M., Wyatt M. D., Hartley J. A., and D’eIncalci M. (1995) DNA sequence specific adenine alkylation by the novel antitumor drug tallimustine (FCE24517), a benzoyl nitrogen mustard derivative of distamycin Nucleic Acids Res 23, 81–87.CrossRefGoogle Scholar
  3. 3.
    Reynolds V. L., Molineux I. J., Kaplan D. J., Swenson D. H., and Hurley L. H. (1985) Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity Biochemistry 24, 6228–6237CrossRefGoogle Scholar
  4. 4.
    Mattes W. B., Hartley J. A., and Kohn K. W. (1986) Mechanism of DNA strand breakage by pipendine at sites of N7-alkylguanines Biochim Biophys Acta 868, 71–76CrossRefGoogle Scholar
  5. 5.
    Sambrook J., Fritsch E. F., and Maniatis T. (1982) Molecular Cloning A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, NYGoogle Scholar
  6. 6.
    Wyatt M. D., Lee M., Garbiras B. J., Souhami R. L., and Hartley J. A. (1995) Sequence specificity of alkylation for a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size, evidence for increased cytotoxicity with enhanced sequence specificity. Biochemistry 34, 13,034–13,041CrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 1997

Authors and Affiliations

  • John A. Hartley
    • 1
  • Michael D. Wyatt
    • 1
  1. 1.Department of Oncology, CRC Drug—DNA Interactions Research GroupUniversity College London Medical SchoolLondonUK

Personalised recommendations